Filing Details
- Accession Number:
- 0001062993-23-019823
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-30 16:12:46
- Reporting Period:
- 2023-10-27
- Accepted Time:
- 2023-10-30 16:12:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1811623 | Paxmedica Inc. | PXMD | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1809613 | Michael Derby | 303 South Broadway, Suite 125 Tarrytown NY 10591 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-10-27 | 9,175 | $0.19 | 439,171 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 7,336,745 | Indirect | TardiMed Sciences, LLC |
Footnotes
- The sales reported in this Form 4 were effected pursuant to the Reporting Person's pre-existing Rule 10b5-1 trading plan to, inter alia, pay tax withholding on vested RSUs.
- The sale price represents the weighted average sale price of the shares sold ranging from $0.186 to $0.191 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The reporting person is the managing partner of TardiMed Sciences, LLC and has sole voting and dispositive control over the shares of Common Stock held by the entity. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- Does not reflect a 1-for-17 reverse stock split effective October 30, 2023.